Bliss GVS Pharma Ltd (BLISSGVS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 730684,
    "name": "Bliss GVS Pharma",
    "stock_name": "Bliss GVS Pharma",
    "full_name": "Bliss GVS Pharma Ltd",
    "name_url": "stocks-analysis/bliss-gvs-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "471.00",
    "chg": -6.25,
    "chgp": "-1.31%",
    "dir": -1,
    "prev_price": "477.25",
    "mcapval": "5,028.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 506197,
    "symbol": "BLISSGVS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE416D01022",
    "curr_date": "Aug 11",
    "curr_time": "",
    "bse_nse_vol": "5.42 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 11, 2026",
    "traded_date_str": "2026 08 11",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/bliss-gvs-pharma-730684-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 296.95",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-ltd-hits-new-52-week-high-at-rs29695-4003082",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BlissGVSPharmaL_priceRelatedfactors_4003082.png",
        "date": "2026-05-21 12:35:33",
        "description": "Surging to a fresh 52-week and all-time high of Rs 296.95 on 21 May 2026, Bliss GVS Pharma Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a volatile backdrop."
      },
      {
        "title": "Strong Momentum Meets Stretched Valuations as Bliss GVS Pharma Reaches All-Time High",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-ltd-stock-hits-all-time-high-on-21-may-2026-4003074",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BlissGVSPharmaL_priceRelatedfactors_4003074.png",
        "date": "2026-05-21 12:11:15",
        "description": ""
      },
      {
        "title": "Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 296.85",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-ltd-hits-new-52-week-high-at-rs29685-3998570",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BlissGVSPharmaL_priceRelatedfactors_3998570.png",
        "date": "2026-05-19 09:39:27",
        "description": "Surging past its previous peaks, Bliss GVS Pharma Ltd touched a new 52-week high of Rs 296.85 on 19 May 2026, marking a remarkable 131.44% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained price strength that has propelled the stock well ahead of the broader market’s subdued performance."
      },
      {
        "title": "Strong Momentum Meets Stretched Valuations as Bliss GVS Pharma Ltd Reaches All-Time High",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-ltd-hits-all-time-high-at-rs-29685-on-19-may-2026-3998532",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BlissGVSPharmaL_priceRelatedfactors_3998532.png",
        "date": "2026-05-19 09:31:06",
        "description": ""
      },
      {
        "title": "Are Bliss GVS Pharma Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-bliss-gvs-pharma-ltd-latest-results-good-or-bad-3989946",
        "imagepath": "",
        "date": "2026-05-13 19:17:37",
        "description": "Bliss GVS Pharma Ltd's latest financial results for the quarter ended March 2026 reveal a complex picture of operational performance. The company reported record revenue of ₹256.99 crores, reflecting a year-on-year growth of 29.80%, which is a notable improvement compared to the previous year's performance. Additionally, net profit surged to ₹35.58 crores, marking a significant year-on-year increase of 128.96%. This performance was further complemented by an operating margin of 17.29%, which also showed substantial year-on-year growth.\n\nDespite these positive quarterly results, there are underlying concerns regarding the company's long-term growth trajectory. The five-year sales compound annual growth rate (CAGR) stands at just 8.97%, while the operating profit (EBIT) has grown at a mere 3.85% annually over the same period. These figures suggest potential structural challenges that could impact future perfo..."
      },
      {
        "title": "Bliss GVS Pharma Ltd Reports Strong Quarterly Upswing Amid Positive Financial Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-ltd-reports-strong-quarterly-upswing-amid-positive-financial-trend-3989468",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BlissGVSPharmaL_fintrenddot_3989468.png",
        "date": "2026-05-13 11:00:08",
        "description": "Bliss GVS Pharma Ltd has demonstrated a marked turnaround in its financial performance for the quarter ended March 2026, upgrading its financial trend from flat to positive. The pharmaceutical micro-cap has posted record quarterly figures across key metrics, signalling renewed operational strength and investor confidence amid a challenging sector backdrop."
      },
      {
        "title": "Strong Momentum Meets Stretched Valuations as Bliss GVS Pharma Ltd Reaches All-Time High",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-ltd-stock-hits-all-time-high-on-13-may-2026-3989356",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BlissGVSPharmaL_priceRelatedfactors_3989356.png",
        "date": "2026-05-13 10:21:07",
        "description": ""
      }
    ],
    "total": 15,
    "sid": "730684",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/bliss-gvs-pharma-730684"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday August 12 2026",
      "datetime": "05-Aug-2026",
      "details": "Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday August 12 2026 at the registered office of the Company to consider and approve inter alia the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.",
      "source": "BSE"
    },
    {
      "caption": "Pre-Offer Advertisement & Corrigendum to Detailed Public Statement",
      "datetime": "27-Jul-2026",
      "details": "SBI Capital Markets Ltd (Manager to the Open Offer) has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended and Corrigendum to the Detailed Public Statement for the attention of the Public Shareholders of Bliss GVS Pharma Ltd (Target Company).",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Cessation",
      "datetime": "24-Jul-2026",
      "details": "Please find attached detailed intimation regarding resignation of Mr. Sachin Saboo Senior Management Personnel of the Company pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "12 Aug 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has declared <strong>100%</strong> dividend, ex-date: 08 Jul 26",
          "dt": "2026-07-08",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has announced <strong>1:10</strong> stock split, ex-date: 11 Mar 08",
          "dt": "2008-03-11",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has announced <strong>3:5</strong> bonus issue, ex-date: 26 Sep 08",
          "dt": "2008-09-26",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 296.95

2026-05-21 12:35:33

Surging to a fresh 52-week and all-time high of Rs 296.95 on 21 May 2026, Bliss GVS Pharma Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a volatile backdrop.

Strong Momentum Meets Stretched Valuations as Bliss GVS Pharma Reaches All-Time High

2026-05-21 12:11:15

Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 296.85

2026-05-19 09:39:27

Surging past its previous peaks, Bliss GVS Pharma Ltd touched a new 52-week high of Rs 296.85 on 19 May 2026, marking a remarkable 131.44% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained price strength that has propelled the stock well ahead of the broader market’s subdued performance.

Strong Momentum Meets Stretched Valuations as Bliss GVS Pharma Ltd Reaches All-Time High

2026-05-19 09:31:06

Are Bliss GVS Pharma Ltd latest results good or bad?

2026-05-13 19:17:37

Bliss GVS Pharma Ltd's latest financial results for the quarter ended March 2026 reveal a complex picture of operational performance. The company reported record revenue of ₹256.99 crores, reflecting a year-on-year growth of 29.80%, which is a notable improvement compared to the previous year's performance. Additionally, net profit surged to ₹35.58 crores, marking a significant year-on-year increase of 128.96%. This performance was further complemented by an operating margin of 17.29%, which also showed substantial year-on-year growth. Despite these positive quarterly results, there are underlying concerns regarding the company's long-term growth trajectory. The five-year sales compound annual growth rate (CAGR) stands at just 8.97%, while the operating profit (EBIT) has grown at a mere 3.85% annually over the same period. These figures suggest potential structural challenges that could impact future perfo...

Bliss GVS Pharma Ltd Reports Strong Quarterly Upswing Amid Positive Financial Trend

2026-05-13 11:00:08

Bliss GVS Pharma Ltd has demonstrated a marked turnaround in its financial performance for the quarter ended March 2026, upgrading its financial trend from flat to positive. The pharmaceutical micro-cap has posted record quarterly figures across key metrics, signalling renewed operational strength and investor confidence amid a challenging sector backdrop.

Strong Momentum Meets Stretched Valuations as Bliss GVS Pharma Ltd Reaches All-Time High

2026-05-13 10:21:07

View All News

Announcement

Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday August 12 2026

05-Aug-2026 | Source : BSE

Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday August 12 2026 at the registered office of the Company to consider and approve inter alia the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.

Pre-Offer Advertisement & Corrigendum to Detailed Public Statement

27-Jul-2026 | Source : BSE

SBI Capital Markets Ltd (Manager to the Open Offer) has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended and Corrigendum to the Detailed Public Statement for the attention of the Public Shareholders of Bliss GVS Pharma Ltd (Target Company).

Announcement under Regulation 30 (LODR)-Cessation

24-Jul-2026 | Source : BSE

Please find attached detailed intimation regarding resignation of Mr. Sachin Saboo Senior Management Personnel of the Company pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Corporate Actions

BOARD MEETING

12 Aug 2026

DIVIDEND

Bliss GVS Pharma Ltd has declared 100% dividend, ex-date: 08 Jul 26

SPLITS

Bliss GVS Pharma Ltd has announced 1:10 stock split, ex-date: 11 Mar 08

BONUS

Bliss GVS Pharma Ltd has announced 3:5 bonus issue, ex-date: 26 Sep 08

RIGHTS

No Rights history available

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support.ra@mojomarkets.in, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."